

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1-39. (Canceled)

40. (Currently Amended) A method of treating a hyperproliferative disease of the skin ~~subject to treatment by inhibition of the retinoic acid biosynthetic pathway, said disease~~ selected from the group consisting of psoriasis, acne vulgaris, actinic ketatosis, solar keratosis, squamous carcinoma in situ, cancers and pre-malignant conditions, ichthyoses, hyperkeratosis and disorders of keratinization; consisting of administering to a patient in need of treatment for a hyperproliferative disease of the skin a pharmaceutical composition, ~~wherein the pharmaceutical composition consists~~ consisting of a single inhibitor of the retinoic acid biosynthetic pathway, ~~which is~~ carbenoxolone and one or more pharmaceutically acceptable ~~carriers, diluents or~~ excipients.

41. (Currently Amended) ~~[[A]]The method of claim 40, wherein said treating a~~ hyperproliferative disease of the skin ~~subject to treatment by inhibition of the retinoic acid biosynthetic pathway, said disease is~~ selected from the group consisting of psoriasis, acne vulgaris, and hyperkeratosis; ~~consisting essentially of administering to a patient in need of treatment for a hyperproliferative disease of the skin a pharmaceutical composition, wherein the pharmaceutical composition consists of a single inhibitor of the retinoic acid biosynthetic pathway, which is~~ carbenoxolone ~~and one or more pharmaceutically acceptable carriers, diluents or~~ excipients.

42. (Currently Amended) ~~[[A]]The method of claim 40, wherein said hyperproliferative disease of the skin is~~ treating psoriasis consisting essentially of administering to a patient in need of treatment for psoriasis a pharmaceutical composition, wherein the pharmaceutical composition

consists of a single inhibitor of the retinoic acid biosynthetic pathway, which is carbenoxolone and one or more pharmaceutically acceptable carriers, diluents or excipients.

43. (Previously Presented) The method of claim 40, wherein the disorder of keratinization is Darier's disease.

44. (Currently Amended) [[A]]The method of claim 40, wherein the pharmaceutical composition is administered topically treating a hyperproliferative disease of the skin subject to treatment by inhibition of the retinoic acid biosynthetic pathway, said disease selected from the group consisting of psoriasis, acne vulgaris, actinic ketatosis, solar keratosis, squamous eareinoma in situ, cancers and pre-malignant conditions, ichthyoses, hyperkeratosis and disorders of keratinization; by topically administering to an affected area of the skin of [[a]]the patient in need of treatment for a hyperproliferative disease of the skin, a pharmaceutical composition consisting of a single inhibitor of the retinoic acid biosynthetic pathway, which is carbenoxolone and one or more pharmaceutically acceptable carriers, diluent or excipients.

45. (Currently Amended) [[A]] The method of claim 44, wherein the treating a hyperproliferative disease of the skin subject to treatment by inhibition of the retinoic acid biosynthetic pathway, said disease is selected from the group consisting of psoriasis, acne vulgaris, and hyperkeratosis; by topically administering to an affected area of the skin of a patient in need of treatment for a hyperproliferative disease of the skin, a pharmaceutical composition consisting of a single inhibitor of the retinoic acid biosynthetic pathway, wherein said inhibitor is carbenoxolone and one or more pharmaceutically acceptable carriers, diluent or excipients.

46. (Currently Amended) [[A]] The method of claim 44, wherein the hyperproliferative disease of the skin treating psoriasis by topically administering to an affected area of the skin of a patient in need of treatment for is psoriasis, a pharmaceutical composition consisting of a single inhibitor of the retinoic acid biosynthetic pathway, wherein said inhibitor is carbenoxolone and one or more pharmaceutically acceptable carriers, diluent or excipients.

47. (Previously Presented) The method of claim 44, wherein the disorder of keratinization is Darier's disease.

48-51. (Canceled)